跳到正文
原文
MedPage Today·· 2 天前AI 评分57

CARES二次分析:痛风发作与心血管事件无关联,支持降尿酸治疗继续使用

No Link Between Gout Flares and Cardiovascular Events in CARES Analysis

AI 导读

CARES试验针对接受target-to-target降尿酸治疗患者的二次分析发现,痛风发作与后续主要不良心血管事件之间无关联,为使用别嘌醇或非布司他的患者提供临床 reassurance。此前英国观察性研究曾提示急性痛风发作与心血管事件有时序关联,本次分析未能复现该结果;研究者指出差异可能源于用药定义不同,且用于处理痛风发作的药物(NSAIDs、糖皮质激素)本身亦与心血管不良事件有关联。

正文

— Findings offer reassurance for patients receiving treat-to-target urate-lowering therapy

by Gregory Laub, Senior Director, Video, MedPage Today

November 18, 2026 • 4 min read

A secondary analysis of the randomized CARES trial, presented at the American College of Rheumatology annual meeting, found no association between gout flares and subsequent cardiovascular events among patients receiving treat-to-target urate-lowering therapy.

In this exclusive MedPage Today video, Chio Yokose, MD, of Massachusetts General Hospital in Boston, discusses how the findings differ from earlier observational research and why they may offer reassurance to clinicians treating patients with gout who have cardiovascular risk factors.

The following is a transcript of her remarks:

People who have gout experience premature mortality compared to those without gout. And this premature mortality persists even after adjusting for traditional cardiovascular-kidney-metabolic risk factors. And one possible explanation for that that has garnered significant attention in recent years is the possibility that the inflammation associated with acute gout flares may be contributing to subsequent cardiovascular events.

This was really highlighted by a prior observational study using some U.K. data that suggested a temporal relationship between acute gout flares and subsequent CV [cardiovascular] events. But whether this pertains to people who are, with gout, who are undergoing urate-lowering therapy as is recommended by the American College of Rheumatology and EULAR [European Alliance of Associations for Rheumatology] in a treat-to-target approach had not yet been examined.

And so we decided to pursue a post-hoc analysis of the CARES trial to look at the association, if present, between gout flares and major adverse cardiovascular events, or MACE, in this population, which was enriched for people with either known cardiovascular disease or risk factors for cardiovascular disease. And everyone as a part of the original trial were randomized to either allopurinol or febuxostat [Uloric] and titrated in a treat-to-target approach.

Basically, we found about 655 cases who experienced MACE in the trial. We matched them on a 1:5 ratio, so just over 3,200 controls without MACE, and found that compared to controls who did not experience MACE, those who did experience MACE in the CARES trial did not have a higher odds of a gout flare in any of the exposure windows we examined.

And furthermore, we conducted multiple subgroup and sensitivity analyses using different gout flare definitions, looking at treated gout flares, focusing on events that occurred within the first year during this period of intense ULT [urate-lowering therapy] initiation and dose escalation. And all across the board, the findings were null. So in this specific population using the CARES study data, we were not able to replicate the findings of the prior U.K. study. And there was no indication that gout flares that occur in the setting of ULT initiations were associated temporally with subsequent cardiovascular events.

The first takeaway, so when the U.K. study came out, it was very interesting. It was a very interesting and cleverly designed study, but it also raised some legitimate clinical questions for those of us who see a lot of patients with gout and prescribe ULT in a treat-to-target approach. Do these associations apply to ULT-induced, what are called paradoxical gout flares or mobilization gout flares? And if so, if these are also linked to MACE, are we actually doing more harm than good?

And so I think our study, using data from a trial that approximated this very clinical scenario in a population that was specifically enriched for people with cardiovascular disease or risk factors, the fact that our findings were negative, I think, is first and foremost reassuring that we can still continue to recommend treat-to-target ULT for the subset of people with gout who qualify and would benefit from it without worrying that we're inducing cardiovascular events by prescribing allopurinol or febuxostat.

And I do think with the discordant results, additional sort of scrutiny about the differences in the study design, the study population, the definitions used for gout flares, are needed. And there's many ways to take that in terms of next steps.

But I think one very relevant question is it's very difficult to disentangle the effect of gout flare medications from the flare inflammation itself. And while colchicine is considered generally protective for the heart, the other two main anti-inflammatory drugs that we use for gout treatment, NSAIDs [nonsteroidal anti-inflammatory drugs] and glucocorticoids themselves have been associated with adverse cardiovascular events, even with short-term use as would often be the case for gout flare treatment.

So trying to tease out the effect of these flare medications versus the flare inflammation on the subsequent cardiovascular risk in people with gout, I think, is important.

来源:MedPage Today · medpagetoday.com